Published in Br J Cancer on January 30, 2006
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer (2011) 1.73
Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene (2007) 1.69
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38
p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol (2012) 1.05
Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One (2009) 1.04
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol (2008) 1.03
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer (2012) 1.02
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr (2010) 1.02
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res (2014) 0.93
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro Oncol (2010) 0.92
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer (2011) 0.88
Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. Oncologist (2011) 0.86
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer (2013) 0.86
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care (Basel) (2010) 0.86
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One (2014) 0.85
Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer (2014) 0.84
Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance. Sci Rep (2015) 0.83
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res (2014) 0.83
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs (2008) 0.82
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer (2010) 0.81
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res (2015) 0.81
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist (2011) 0.79
Retracted Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer (2014) 0.79
Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer (2015) 0.78
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001). Mol Clin Oncol (2012) 0.78
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J Cancer Res (2016) 0.77
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A (2016) 0.77
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. BMC Cancer (2016) 0.77
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol (2015) 0.77
Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) (2008) 0.75
Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. J Mammary Gland Biol Neoplasia (2017) 0.75
The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep (2016) 0.75
t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit. Cell Signal (2017) 0.75
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 16.92
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (2001) 5.24
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32
The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem (2001) 4.00
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A (1998) 3.05
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
Ras signalling and apoptosis. Curr Opin Genet Dev (1998) 2.63
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene (2000) 2.19
Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol (2001) 2.11
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene (1999) 2.07
Breast cancer--loss of PTEN predicts resistance to treatment. N Engl J Med (2004) 1.91
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer (1999) 1.54
Overexpression of p53 and prognosis in breast cancer. Cancer (1993) 1.51
A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet (1995) 1.45
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer (2004) 1.42
Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene (1998) 1.38
Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer (1998) 1.30
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat (1999) 1.22
Efficacy of trastuzumab. Cancer Res (2005) 1.22
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res (2004) 1.20
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res (2004) 1.14
Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses (2005) 1.06
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol (2003) 1.01
Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst (2001) 1.01
Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer (1996) 1.00
Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell (2004) 0.89
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
The DNA sequence of human chromosome 22. Nature (1999) 30.88
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
A physical map of the human genome. Nature (2001) 12.39
The DNA sequence of human chromosome 21. Nature (2000) 10.66
Primary structure of Electrophorus electricus sodium channel deduced from cDNA sequence. Nature (1984) 8.02
Existence of distinct sodium channel messenger RNAs in rat brain. Nature (1986) 7.87
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet (1997) 7.59
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature (1987) 6.66
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
Positional cloning of the APECED gene. Nat Genet (1997) 5.47
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature (1986) 4.97
Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol (2001) 4.96
Heterogeneity of the principal sigma factor in Escherichia coli: the rpoS gene product, sigma 38, is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli. Proc Natl Acad Sci U S A (1993) 4.92
Structural homology of Torpedo californica acetylcholine receptor subunits. Nature (1983) 4.70
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63
Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet (1994) 4.36
Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A (1985) 4.28
Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Primary structure of alpha-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature (1982) 3.69
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64
Guidelines for calibration of stimulus and recording parameters used in clinical electrophysiology of vision. Calibration Standard Committee of the International Society for Clinical Electrophysiology of Vision (ISCEV). Doc Ophthalmol (1998) 3.39
Primary structure of the alpha-subunit of transducin and its relationship to ras proteins. Nature (1985) 3.28
Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature (1982) 3.09
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet (1996) 3.07
Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol (1991) 3.07
Modified formalin test: characteristic biphasic pain response. Pain (1989) 3.00
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int (2006) 3.00
Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature (1982) 2.79
A consensus linkage map of the chicken genome. Genome Res (2000) 2.79
Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor. Nature (1983) 2.78
Nonsense mutation of glucokinase gene in late-onset non-insulin-dependent diabetes mellitus. Lancet (1992) 2.71
Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med (1995) 2.63
Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res (1994) 2.61
Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science (1991) 2.56
Pulmonary function, postoperative pain, and serum cytokine level after lobectomy: a comparison of VATS and conventional procedure. Ann Thorac Surg (2001) 2.55
Primary structures of beta- and delta-subunit precursors of Torpedo californica acetylcholine receptor deduced from cDNA sequences. Nature (1983) 2.55
Cloning and nucleotide sequence of phoP, the regulatory gene for alkaline phosphatase and phosphodiesterase in Bacillus subtilis. J Bacteriol (1987) 2.52
Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med (1999) 2.51
A SNP resource for human chromosome 22: extracting dense clusters of SNPs from the genomic sequence. Genome Res (2001) 2.49
A spin-valve-like magnetoresistance of an antiferromagnet-based tunnel junction. Nat Mater (2011) 2.47
Effects of size and shape (aspect ratio) on the hemodynamics of saccular aneurysms: a possible index for surgical treatment of intracranial aneurysms. Neurosurgery (1999) 2.43
Infectious cell entry mechanism of influenza virus. J Virol (1982) 2.41
Periodic emission from the gamma-ray binary 1FGL J1018.6-5856. Science (2012) 2.40
Location of functional regions of acetylcholine receptor alpha-subunit by site-directed mutagenesis. Nature (1985) 2.40
Primary structure of rat brain sodium channel III deduced from the cDNA sequence. FEBS Lett (1988) 2.39
Structure of the 5' upstream region and the regulation of the rpoS gene of Escherichia coli. Mol Gen Genet (1994) 2.38
Interaction of influenza virus hemagglutinin with target membrane lipids is a key step in virus-induced hemolysis and fusion at pH 5.2. Proc Natl Acad Sci U S A (1981) 2.31
Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol (1997) 2.31
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30
Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J Virol (1989) 2.28
Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet (1986) 2.27
Cloning and chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. J Biol Chem (1994) 2.22
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. Gastroenterology (1994) 2.20
Hemolytic activity of influenza virus hemagglutinin glycoproteins activated in mildly acidic environments. Proc Natl Acad Sci U S A (1983) 2.20
Inorganic polyphosphate and the induction of rpoS expression. Proc Natl Acad Sci U S A (1997) 2.19
Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia (1993) 2.11
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10
Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest (1999) 2.09
An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 2.08
Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet (1993) 2.07
Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology (1992) 2.07
Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet (2001) 2.06
Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut (2008) 2.05
Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett (1986) 2.03
Nucleotide sequence of the Bacillus subtilis phoR gene. J Bacteriol (1988) 2.02
Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A (1987) 2.02
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
Abortive bacteriophage T4 head assembly in mutants of Escherichia coli. J Mol Biol (1973) 2.00
Thoracoscopic operation for secondary pneumothorax under local and epidural anesthesia in high-risk patients. Ann Thorac Surg (1998) 1.99
Neuromyelitis optica preceded by hyperCKemia episode. Neurology (2010) 1.94
Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology (1991) 1.94
Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc Natl Acad Sci U S A (2001) 1.93
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax (1999) 1.93
Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet (2000) 1.92
Detection and recovery of mycobacteria by a radiometric procedure. J Clin Microbiol (1983) 1.92
Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet (1998) 1.91
Epidemiology of influenza A(H1N1)v virus infection in Japan, May-June 2009. Euro Surveill (2009) 1.91
Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining. Cancer (1995) 1.91
Regulation of band 3 mobilities in erythrocyte ghost membranes by protein association and cytoskeletal meshwork. Biochemistry (1988) 1.89
The effect of spo0 mutations on the expression of spo0A- and spo0F-lacZ fusions. Mol Gen Genet (1986) 1.89
Treatment of gallbladder cancer by radical resection. Br J Surg (1999) 1.88
Manipulation of the small intestine as a cause of the increased inflammatory response after open compared with laparoscopic surgery. Br J Surg (2006) 1.88
Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol (2007) 1.87
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol (1999) 1.86